Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 24 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Panacea Biotec Ltd

About the Company - Panacea Biotec Ltd

Panacea Biotec Ltd. is a Public Limited Listed company incorporated on 02/02/1984 and has its registered office in the State of Punjab, India. Company’s Corporate Identification Number(CIN) is L33117PB1984PLC022350 and registration number is 022350. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 235.50 Cr. and Equity Capital is Rs. 6.13 Cr. for the Year ended 31/03/2022.
PharmaceuticalsAmbala-Chandigarh Highway, Lalru Punjab
NamePosition Held
Dr. Rajesh JainChairman & Managing Director
Mr. Sandeep JainJoint Managing Director
Mr. Ankesh JainWhole Time Director
Mr. R L NarasimhanNon Executive Director
Mr. N N KhamitkarNon Executive Director
Mr. K M LalNon Executive Director
Mrs. Manjula UpadhyayNon Executive Director
Mr. Bhupinder SinghNon Executive Director
Mr. Mukul GuptaNon Executive Director
Mr. Narotam Kumar JunejaNon Executive Director

Panacea Biotec Ltd. Share Price Update

Share PriceValue
Previous Day₹160.15

Basic Stock Data of Panacea Biotec Ltd

Market Cap 1,003 Cr.
Current Price 164
High / Low202/107
Stock P/E
Book Value 138
Dividend Yield0.00 %
ROCE10.3 %
ROE10.9 %
Face Value 1.00

Data Source:

Competitors of Panacea Biotec Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Marksans Pharma Ltd 7,137 Cr. 158179/64.322.5 41.40.32 %22.2 %18.6 % 1.00
Venus Remedies Ltd 488 Cr. 365430/14716.8 3520.00 %7.75 %5.90 % 10.0
Kwality Pharmaceuticals Ltd 529 Cr. 510545/24818.6 2060.00 %18.5 %16.5 % 10.0
Alembic Pharmaceuticals Ltd 20,816 Cr. 1,0591,094/46235.2 2270.75 %7.40 %7.20 % 2.00
Bafna Pharmaceuticals Ltd 220 Cr. 92.9126/77.019.5 34.80.00 %15.9 %16.4 % 10.0
Industry Average252.8 Cr225.3822.52172.240.21%14.35%12.92%6.6

Panacea Biotec Ltd Quarterly Results

MonthSep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Operating Profit37.5815.100.94-1.556.0211.86-30.19-79.81-3.84-8.64-5.67-10.31-3.56
OPM %20.65%10.65%0.56%-1.17%2.59%7.61%-21.45%-72.10%-3.65%-7.50%-4.40%-7.98%-2.49%
Other Income2.071.894.903.232.031.661,680.2639.9538.2241.7134.4433.826.00
Profit before tax-19.24-40.01-52.65-57.27-53.01-49.161,608.26-51.1623.3122.4418.2113.03-7.78
Tax %-0.47%-0.10%-2.83%-0.14%0.00%-0.08%23.06%-9.73%32.65%13.68%169.63%15.73%-6.56%
Net Profit-19.33-40.05-54.14-57.35-53.01-49.201,237.47-56.1415.7019.37-12.6810.98-8.29
EPS in Rs-3.15-6.54-8.83-9.36-8.65-8.03201.86-9.162.563.16-2.071.79-1.35

Panacea Biotec Ltd Quarterly Chart

Panacea Biotec Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit-63-56-72441123984-1345477-13-98-28
OPM %-9%-9%-14%6%17%7%14%-29%10%12%-2%-21%-5%
Other Income-15-71832870628338-1491,687154116
Profit before tax-255-253-111-99-19-67-6645-178-1461,4491346
Tax %21%7%-2%-3%-10%16%-15%17%-9%-1%26%363%
Net Profit-206-234-113-108-21-56-7638-194-1481,078-349
EPS in Rs-33.55-38.22-18.29-17.38-2.98-8.89-12.076.15-31.69-24.09175.91-5.421.53
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Panacea Biotec Ltd Profit & Loss Yearly Chart

Panacea Biotec Ltd Growth

Compounded Sales Growth
10 Years:-3%
5 Years:-5%
3 Years:-5%
Compounded Profit Growth
10 Years:5%
5 Years:-6%
3 Years:12%
Stock Price CAGR
10 Years:7%
5 Years:-1%
3 Years:-7%
1 Year:33%
Return on Equity
10 Years:%
5 Years:%
3 Years:%
Last Year:-11%

Panacea Biotec Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital6666666666666
Preference Capital00016160000000
Other Liabilities198235371381334440349379481587848407404
Total Liabilities1,9501,8391,9431,9301,8541,7891,5981,3761,3901,1781,7591,2711,272
Fixed Assets1,1951,1541,2761,1441,0711,001949806657609622600624
Other Assets6315274796166147506025427035341,114615562
Total Assets1,9501,8391,9431,9301,8541,7891,5981,3761,3901,1781,7591,2711,272

Panacea Biotec Ltd Reserves and Borrowings Chart

Panacea Biotec Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 228-24543791131118105-30107-108-422
Cash from Investing Activity -124-61-38-3716-2655-6-35-481,283430
Cash from Financing Activity -134105-30-1-117-107-164-10191-47-1,176-18
Net Cash Flow-2920-14-1-10-29-22612-2-10

Panacea Biotec Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days354268527995847146494548
Inventory Days405371375404516770651173344311296292
Days Payable128243430272318607540572463440327256
Cash Conversion Cycle31117013184278259195-328-73-801483
Working Capital Days11292-11331134826-307976-229-7
ROCE %-8%-8%-8%0%4%2%3%-16%4%6%-6%-10%

Panacea Biotec Ltd Financial Efficiency Indicators Chart

Panacea Biotec Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
No. of Shareholders27,02827,22854,31352,81652,46549,56349,89649,07850,53348,63447,81548,878

Panacea Biotec Ltd Shareholding Pattern Chart

No. of Panacea Biotec Ltd Shareholders

Panacea Biotec Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Motilal Oswal S&P BSE Healthcare ETF1170.020

Panacea Biotec Ltd ROCE Trend

Panacea Biotec Ltd EPS Trend

Panacea Biotec Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)-5.43175.98-24.11-31.726.15
Diluted EPS (Rs.)-5.43175.98-24.11-31.726.15
Cash EPS (Rs.)0.87183.11-16.68-24.7214.94
Book Value[Excl.RevalReserv]/Share (Rs.)133.63138.09-41.3628.4055.14
Book Value[Incl.RevalReserv]/Share (Rs.)133.63138.09-41.3628.4055.14
Revenue From Operations / Share (Rs.)75.09107.96102.0188.8374.56
PBDIT / Share (Rs.)-7.56-0.4714.149.97-20.69
PBIT / Share (Rs.)-13.95-7.606.702.91-29.50
PBT / Share (Rs.)2.09236.54-23.56-28.017.91
Net Profit / Share (Rs.)-5.51175.98-24.12-31.786.13
NP After MI And SOA / Share (Rs.)-5.43175.98-24.11-31.726.16
PBDIT Margin (%)-10.06-0.4313.8611.22-27.74
PBIT Margin (%)-18.57-7.046.563.27-39.56
PBT Margin (%)2.78219.10-23.09-31.5310.61
Net Profit Margin (%)-7.33163.01-23.64-35.778.21
NP After MI And SOA Margin (%)-7.22163.01-23.63-35.708.26
Return on Networth / Equity (%)-4.04126.990.00-109.7511.07
Return on Capital Employeed (%)-9.09-4.755.441.90-41.32
Return On Assets (%)-2.6160.47-12.52-13.972.74
Long Term Debt / Equity (X)0.010.03-2.923.450.10
Total Debt / Equity (X)0.010.03-2.923.470.30
Asset Turnover Ratio (%)0.300.240.310.120.06
Current Ratio (X)1.711.301.201.500.54
Quick Ratio (X)
Inventory Turnover Ratio (X)
Interest Coverage Ratio (X)-10.43-0.010.460.35-1.21
Interest Coverage Ratio (Post Tax) (X)-29.74-2.310.210.01-1.80
Enterprise Value (Cr.)454.38355.931682.861194.591302.99
EV / Net Operating Revenue (X)0.980.532.692.202.85
EV / EBITDA (X)-9.81-122.8619.4319.57-10.28
MarketCap / Net Operating Revenue (X)1.441.371.741.232.66
Price / BV (X)0.801.07-4.343.793.56
Price / Net Operating Revenue (X)1.441.371.741.232.66

Panacea Biotec Ltd Profitability Ratios (%)

Panacea Biotec Ltd Liquidity Ratios

Panacea Biotec Ltd Liquidity Ratios (%)

Panacea Biotec Ltd Interest Coverage Ratios (%)

Panacea Biotec Ltd Valuation Ratios

Fair Value / Intrinsic Value of Panacea Biotec Ltd

Fair Value: ₹230.14

The stock is undervalued by 40.33% compared to the current price ₹164

*Investments are subject to market risks

Strength and Weakness of Panacea Biotec Ltd

  1. The stock has a low average Working Capital Days of -8.00, which is a positive sign.
  2. The company has higher reserves (487.92 cr) compared to borrowings (2.46 cr), indicating strong financial stability.
  1. The stock is trading at a high valuation with an average P/B ratio of -8.29 and average Dividend Yield of -11.07%.
  2. The stock has a low average ROCE of -3.08%, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 85.50, which may not be favorable.
  4. The company has not shown consistent growth in sales (582.15) and profit (-83.77).

Should I Buy Panacea Biotec Ltd?

  • Considering various financial indicators, investors might exercise caution regarding investment in Panacea Biotec Ltd:
    1. Net Profit Margin: -7.33%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: -9.09% (Industry Average ROCE: 14.27%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. Interest Coverage Ratio (Post Tax): -29.74
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    4. Quick Ratio: 1.10
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    5. ✓ Stock P/E of N/A (Industry average Stock P/E: 27.04)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    6. ✓ Total Debt / Equity: 0.01
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis suggests exercising caution. It's advisable to conduct further research or consult with financial experts before considering any investment.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Panacea Biotec Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE